Any current/future capex/capital investment/strategic investment?

For FY27, Emcure Pharmaceuticals plans a capital expenditure (capex) of approximately INR 400-425 crores. The company continues to invest in R&D, with FY26 R&D investments at INR 383.5 crores (4.2% of revenue), supporting pipeline development in complex injectables, biosimilars, novel delivery routes, and Antibody Drug Conjugates (ADC). Strategic investments include in-licensing deals (e.g., partnership with Novo Nordisk for Poviztra, expanded partnership with Sanofi for Amaryl & Cetapin, and distribution agreement with Roche for nephrology drugs). Mergers and acquisitions highlight cons

Future growth expectations in sales/revenue/volumes?

Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets. Domestic market expected to grow faster than industry (~8-9%) at low double-digits, supported by strong teams and portfolios in cardio-diabetes, biologics, women's health, and new initiatives. International markets (Europe, Canada, Emerging markets) expected to maintain strong growth, with Europe's business projected for mid-teens CAGR over the next 2 years. Amphotericin B launch is a key growth driver. Growth levers i

Future growth expectations in earnings/operating earnings/profits/EPS?

Emcure expects low to mid-teen revenue growth in FY27 and beyond. EBITDA margins are projected to expand by 75 to 100 basis points annually, driven by operating leverage and productivity gains. Adjusted PAT grew over 40% in FY26, indicating strong profit growth traction. Continued margin expansion is anticipated through scale benefits and synergy realization. Growth drivers include domestic market strength (especially Cardio-Diabetes, biologics, women's health), semaglutide partnership, Emcutix derma product, consumer health segment, and international markets (Canada, Europe, Emerging Markets)

Current/ Expected Orderbook/ Pending Orders?

Emcure's non-ARV business, which is crucial for revenue diversification, maintains a strong order book. The HIV segment continues to enjoy a pole position with a robust ARV order book. The company has ongoing registrations in various markets supporting this strong order book. Emcure filed the DMF for Gilead Lenacapavir and expects product registration in FY27, indicating pending orders in the pipeline. Overall, international markets show sustained growth driven by a robust order book in ARV and non-ARV segments.

IN US

Sale is live|00:00:00left today

Emcure Pharmaceuticals LtdQ1 FY26Pharmaceuticals & Biotechnology

Emcure Pharmaceuticals Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,880P/E: 34.2Market Cap: ₹32.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets.
→Domestic market expected to grow faster than industry (~8-9%) at low double-digits, supported by strong teams and portfolios in cardio-diabetes, biologics, women's health, and new initiatives.
→International markets (Europe, Canada, Emerging markets) expected to maintain strong growth, with Europe's business projected for mid-teens CAGR over the next 2 years. Amphotericin B launch is a key growth driver.
→Growth levers include ramp-up of semaglutide partnership, dermal product Emcutix, consumer business Arth, and new launches.
→Biosimilar market expected to heat up due to lowered FDA R&D requirements; Emcure’s experience positions it well to thrive.
→Focus on execution, processes, people, and optimized margins will support sustained above-industry growth and margin expansion by 75-100 basis points annually.

Margin guidance

Category 2

→Emcure expects low to mid-teen revenue growth in FY27 and beyond.
→EBITDA margins are projected to expand by 75 to 100 basis points annually, driven by operating leverage and productivity gains.
→Adjusted PAT grew over 40% in FY26, indicating strong profit growth traction.
→Continued margin expansion is anticipated through scale benefits and synergy realization.
→Growth drivers include domestic market strength (especially Cardio-Diabetes, biologics, women's health), semaglutide partnership, Emcutix derma product, consumer health segment, and international markets (Canada, Europe, Emerging Markets).
→Amphotericin B launch and biosimilars (like Bevacizumab) are expected to contribute to near-term profitability.
→Emcure aims for sustainable above-industry growth with margin improvement and long-term value creation.
→Management is confident of execution delivering results consistent with market expectations going forward.

3 more insights locked — sign up free to unlock

Fundraise plans

The provided transcript does not mention any current or future fundraising plans through debt or equity for Emcure Pharmaceuticals Limited. Key points related to finances and strategic plans include: - No mention of debt or equity fundraising in the Q&A or management comments. - Focus is on organic growth, execution, and operational improvements. - Growth drivers include domestic market expansion, semaglutide partnership, new product launches, and international market growth. - Emphasis on improving margins and delivering sustainable above-industry growth. - Completed minority stake buyout of Zuventus for full consolidation, but no note on raising new funds. Therefore, based on the transcript on page 20 and related content, there is no disclosed plan for any new fundraising via debt or equity in the near future.

Order book

Yes

→Emcure's non-ARV business, which is crucial for revenue diversification, maintains a strong order book.
→The HIV segment continues to enjoy a pole position with a robust ARV order book.
→The company has ongoing registrations in various markets supporting this strong order book.
→Emcure filed the DMF for Gilead Lenacapavir and expects product registration in FY27, indicating pending orders in the pipeline.
→Overall, international markets show sustained growth driven by a robust order book in ARV and non-ARV segments.

Capex plans

Yes

→For FY27, Emcure Pharmaceuticals plans a capital expenditure (capex) of approximately INR 400-425 crores.
→The company continues to invest in R&D, with FY26 R&D investments at INR 383.5 crores (4.2% of revenue), supporting pipeline development in complex injectables, biosimilars, novel delivery routes, and Antibody Drug Conjugates (ADC).
→Strategic investments include in-licensing deals (e.g., partnership with Novo Nordisk for Poviztra, expanded partnership with Sanofi for Amaryl & Cetapin, and distribution agreement with Roche for nephrology drugs).
→Mergers and acquisitions highlight consolidation in the UK (Manx portfolio), Canada (Cutimed derma range), and full consolidation of Zuventus business in India.
→Future growth will focus on execution, people, process improvements, and geographic diversification (India, Canada, Europe, Emerging Markets).

How does Emcure Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Emcure Pharmaceuticals Ltd

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Emcure Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio